Healthcare Industry News: Age-related Macular Degeneration
News Release - April 30, 2010
IRIDEX Announces First Commercial Shipment of New IQ 532(TM) Laser SystemsSecond New Laser Introduced within One Year Based on Common Platform
MOUNTAIN VIEW, Calif., April 30 (Healthcare Sales & Marketing Network) -- IRIDEX Corporation, (Nasdaq:IRIX ) today announced the commencement of commercial shipment of the IQ 532 laser systems. The IQ 532 is a high-power, 532 nm, dual port multi-purpose laser system for use by ophthalmologists to treat sight-threatening eye diseases such as diabetic retinopathy, Age-related Macular Degeneration and glaucoma; and for use by otolaryngologists to correct certain types of conductive hearing loss.
"The time and effort we invested to perfect our core system platform and obtain regulatory approval for a family of laser products has made it possible to introduce the IQ 532 green laser within one year of shipping the IQ 577 yellow laser," commented Theodore A. Boutacoff, President and Chief Executive Officer of IRIDEX. "Continuing with this platform approach, we look forward to the timely introduction of additional systems currently under development."
As with the IQ 577, the IQ 532 features dual port laser output as well as a graphic, touchscreen interface. Dual port connectivity provides the physician with the added convenience and efficiency by permitting the exchange of multiple delivery devices with one-touch speed and simplicity. Setup and use of the IQ 532 system for surgery is quick, easy and intuitive, thanks to its superior ergonomics and user interface.
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, relating to IRIDEX's statements relating to our common platform approach, the benefits of such approach and future product development. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 2, 2010, which was filed with the Securities and Exchange Commission on March 31, 2010. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.